Pune: FDA Busts Fake Chymoral Forte Tablet Network, Multi-State Probe Leads Investigators to Bihar
Pune: FDA Busts Fake Chymoral Forte Tablet Network, Multi-State Probe Leads Investigators to Bihar
Pune, December 11, 2025: The Food and Drugs Administration (FDA), Pune Division, has launched a major investigation after receiving confidential information about the sale of counterfeit Trypsin–Chymotrypsin (Chymoral Forte) tablets in Pune. The fake medicines bore the details: Batch No. 2KU6L055, Mfg Date: Dec 2024, Exp Date: Nov 2027, Mfg Lic No. M/564/2010, and falsely claimed to be manufactured by Torrent Pharmaceuticals Ltd., Sikkim.
Acting on the tip-off, FDA drug inspectors collected samples from Akshay Pharma, Sadashiv Peth, Pune on 16 October 2025 for testing and analysis. The sample was also sent to Torrent Pharmaceuticals Ltd., Sikkim for verification.
During the investigation, Akshay Pharma stated that they had purchased the stock from Arjas Medical Distributor, Sadashiv Peth, who in turn had sourced it from Riddhi Pharma, Erandwane. Further inquiry revealed that Riddhi Pharma had procured the medicines from Sena Pharma, Lucknow (UP).
A team of FDA inspectors, Srikant Patil and Vivek Khedkar, conducted an on-ground investigation in Lucknow between 24–27 November 2025. Sena Pharma revealed that they had purchased the stock from Mahival Medico, Gopalganj, Bihar, paying ₹2,34,727.94 in cash to a person named Umang Rastogi, who then transferred the amount in cash to Mahesh Garg. Sena Pharma confirmed that they received the counterfeit stock from Mahesh Garg through unregistered sources.
The FDA, Pune, later contacted the Assistant Drugs Controller in Gopalganj, Bihar, who reported that Mahival Medico had shut down and its license had expired on 20 November 2024, raising further suspicion.
Meanwhile, Torrent Pharmaceuticals Ltd., Sikkim, completed their comparative study and confirmed that the seized tablets were not manufactured by them, officially validating that the batch in circulation was counterfeit.
Further investigation into the supply chain and responsible individuals is ongoing as the FDA intensifies its crackdown on the distribution of fake medicines in Pune and other states.
